Compare Becton Dickinson and Co (BDX) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Moody's Corporation — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Moody's Corporation trades at $476.73 (market cap $82.80B). The key difference: Moody's Corporation is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.
| BDX | MCO | |
|---|---|---|
Market Cap | $48.93B | $82.80B |
Sector | Health | Financials |
52-Week High | $185.39 | $539.61 |
52-Week Low | $138.62 | $412.23 |
Enterprise Value | $65.03B | $88.83B |
Dividend Yield | 2.34% | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
MCO trades at $477.75, up 0.98% on the day, with a bullish technical signal and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $4.68 versus $4.26 expected, driven by robust debt issuance and analytics demand. Revenue growth accelerated to 15% year-over-year, with net income margin expanding to 34.25%. The stock is supported by a consensus price target of $561.88, indicating 17.6% upside potential, and positive analyst sentiment with 56% buy ratings.
Outlook remains positive due to consistent earnings beats, high profitability, and strategic positioning in credit ratings. Risks include elevated valuation multiples, such as a P/E of 30.31, and dependence on capital market activity. Investors should weigh growth prospects against potential macroeconomic headwinds affecting debt issuance volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
